Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.WellSpring Pharmaceutical has expanded its consumer healthcare product line by concluding a transaction with McNeil Consumer Healthcare division of McNeil PPC wherein WellSpring has purchased several over-the-counter consumer drug products.
Subscribe to our email newsletter
In an all-cash transaction, WellSpring has purchased the US rights to Micatin (antifungal), Emetrol (anti-nausea), and Gelusil (antacid), and the Canadian rights to Micatin, Gelusil and Glycerin Suppositories (laxative).
WellSpring Pharmaceutical said that the acquisition of these brands further strengthens the company’s consumer product business in Canada where they join Glaxal Base, Barriere (skin care products), Dequadin (cough/cold), Replens (vaginal moisturizer), K-Lyte (potassium supplement), and others. In the US the new brands give WellSpring a base in the consumer healthcare marketplace soon to be joined by the launch of Glaxal Base and Barriere.
Robert Vukovich, president and CEO of WellSpring, said: “Having marketed over-the-counter products in Canada for many years, our experience in growing this pharmaceutical category should prove to be very beneficial. WellSpring expects to undertake an aggressive marketing effort to re-invigorate these products and expand their distribution.”